ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

ME Staff 8-k
-
0

ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.

(d)

On February 16, 2017, the Board of Directors (the Board) of ARCA
biopharma, Inc. (the Company) elected Anders Hove, M.D., as a
director of the Company. In connection with Dr. Hoves election,
Dr. Hove and the Company entered into an Indemnity Agreement, in
the same form used with the Companys other directors. The
Indemnity Agreement generally requires the Company to indemnify
Dr. Hove against liabilities incurred in the performance of his
duties to the Company to the maximum extent permitted by Delaware
corporate law and the Companys certificate of incorporation and
bylaws. The Companys standard form of Indemnity Agreement is
filed as Exhibit 10.52 to its Annual Report on Form 10-K filed on
March 27, 2009.

(e)

On February 27, 2017, the Compensation Committee of the Board of
Directors (the Board) of the Company approved the following stock
option (Options) grants to the executive officers listed below to
the Companys Amended and Restated 2013 Equity Incentive Plan and
the forms of Stock Option Grant Notice and Option Agreement for
officers, as filed with the Securities and Exchange Commission as
exhibits to the Companys Current Report on Form 8-K on September
23, 2013:

Name and Title

Options

Granted (1)

Michael Bristow

President and Chief Executive Officer

41,600

Thomas A. Keuer

Chief Operating Officer

23,800

Christopher Ozeroff

Senior Vice President, General Counsel Secretary

22,700

Brian L. Selby

Vice President, Finance

24,100

(1)

Exercise price of $2.60 per share, the closing price of
the Companys common stock on the Nasdaq Capital Market on
February 27, 2017. Each Option can vest 50% upon
achievement of a certain pre-specified corporate
milestone related to the timing and outcome of the
interim data analysis by that trials Data and Safety
Monitoring Board, and if the milestone is achieved, the
remainder of the grant will vest on March 31, 2018.If the
corporate milestone is not achieved, the Option will be
cancelled.


About ARCA biopharma, Inc. (NASDAQ:ABIO)

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

ARCA biopharma, Inc. (NASDAQ:ABIO) Recent Trading Information

ARCA biopharma, Inc. (NASDAQ:ABIO) closed its last trading session 00.00 at 2.55 with 24,664 shares trading hands.